We demonstrated the effectiveness of the dual mTORC1-2 inhibitor Rapalink-1 in reducing PCa tumor growth, an effect that was associated with the depletion of CD44+ cells in a PDX model of advanced, bone metastatic PCa. This evidence concerns the gene CD44 and neoplasm.